TYK2 Inhibitor Pipeline Shaping the Next Generation of Autoimmune Disease Therapy

The TYK2 inhibitor market is currently characterized by a single commercial product and a rapidly expanding development pipeline. Deucravacitinib (Sotyktu) was developed by Bristol Myers Squibb and approved by the US Food and Drug Administration in 2022. Available in tablet form, SOTYKTU is indicated for the treatment of adults with moderate to severe plaque psoriasis. Additional approvals in Europe in 2026 and expansion into psoriatic arthritis have further strengthened its market position. Revenue Performance of SOTYKTU, 2022–2025 (USD Million) The historical revenue performance of Sotyktudemonstrates strong commercial growthsince its launch in 2022. Revenue increased significantly due to increased physician adoption, expanded market access, and growing patient uptake. The consistent year-over-year revenue growth highlights the increasing acceptance of TYK2-targeted therapies for autoimmune diseases, particularly in plaque psoriasis and psoriatic arthritis. Although late-stage pipeline candidates such as zasocitinib and envudeucitinib are expected to enter the market over the next few years, Sotyktu is likely to maintain a strong competitive position, supported by indication expansions and wider geographic reach. Clinical Trials Landscape The competitive landscape is evolving rapidly, with various biotechnology and pharmaceutical companies developing next-generation TYK2 inhibitors with improved safety, high TYK2 selectivity, and expansion into multiple autoimmune indications. Tyrosine Kinase 2 (TYK2) Inhibitors Clinical Pipeline Company Product Candidate Mechanism/Selectivity Development Phase Indication Bristol Mysers Squibb Deucravacitinib (Sotyktu) Highly selective allosteric TYK2 inhibitor Phase III Psoriatic Arthritis Takeda Zasocitinib (TAK-279) Ultra-selective allosteric TYK2 inhibitor Phase III Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis Alumis Envudeucitinib (ESK-001) Selective allosteric TYK2 inhibitor Phase III Plaque psoriasis; Phase IIb in Systemic Lupus Erythematosus (SLE) A-005 Next-generation TYK2 inhibitor Phase I Parkinson's disease (neuroinflammation) Pfizer Inc. Brepocitinib (PF-06700841) Dual TYK2/JAK1 inhibitor Phase III Dermatomyositis, inflammatory bowel disease and other immune-mediated disorders Priovant brepocitinib Dual TYK2/JAK1 inhibitor Phase III Non-infectious uveitis Sudo Biosciences SUDO-550 TYK2 inhibitor Completed phase II Neuroinflammatory diseases InnoCare Pharma soficitinib (ICP-332) Novel TYK2 inhibitor Phase II/III Chronic spontaneous urticaria The TYK2 inhibitor landscape is expected to evolve with new product approvals over the next few years. Among the investigational candidates, zasocitinib (TAK-279) developed by Takeda and envudeucitinib (ESK-001) developed by Alumis have emerged as the most advanced competitors, demonstrating promising efficacy and safety profiles in late-stage clinical trials for plaque psoriasis and other immune-mediated disorders. A key trend across the pipeline is the industry's emphasis on highly selective allosteric TYK2 inhibition, which offers targeted modulation of immune signaling while potentially reducing the safety concerns associated with conventional ATP-competitive JAK inhibitors. As a result, next-generation TYK2 inhibitors are being positioned to deliver improved efficacy, enhanced tolerability, and long-term treatment suitability, thereby strengthening their competitive value proposition in the autoimmune therapeutics market.